Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Giovanni Marchegiani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6824-4533; OpenAlex author ID A5029679816. Sources: OpenAlex.

Their work

Papers
49 (first author 8, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
186
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 8 papers · 2019: 2 papers · 2020: 5 papers · 2021: 3 papers · 2022: 3 papers · 2023: 3 papers · 2024: 4 papers · 2025: 6 papers · 2026: 12 papers

Papers 49

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  3. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  4. The projected rise of pancreatic cancer mortality in Italy: forecasts until 2035. Last author DOI 10.1007/s13304-026-02862-w↗
  5. The future of integrated treatment for PDAC: Learning from the past, advancing for the better. First author DOI 10.1016/j.dld.2026.09.002↗
  6. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  7. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  8. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  9. Conversion surgery vs. standard of care in pancreaTic cancer oligometastatic to the liver (SONAR: Surgery in Oligometastatic paNcreatic cAnceR) a randomized co… Co-author DOI 10.1186/s12885-025-15183-9↗
  10. Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with… Last author DOI 10.1245/s10434-026-19939-w↗
  11. ASO Visual Abstract: Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapie… Last author DOI 10.1245/s10434-026-19987-2↗
  12. ASO Author Reflections: Local Therapy for Single-Site Recurrent Pancreatic Cancer: Anatomy, Biology, and Selection. Last author DOI 10.1245/s10434-026-20012-9↗
  13. Complications following upfront pancreatectomy with venous resection do not compromise adjuvant chemotherapy delivery and survival in pancreatic cancer. Last author DOI 10.1007/s00423-025-03933-z↗
  14. Reducing the burden of pancreatic cancer by surveilling mucinous cystic neoplasms: are we there yet? Co-author DOI 10.1016/j.bpg.2025.101998↗
  15. Association of Smoking with progression from low-risk to high-risk intraductal papillary mucinous neoplasms and pancreatic cancer. Co-author DOI 10.1016/j.dld.2024.05.017↗
  16. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  17. Introducing 'borderline observable' intraductal papillary mucinous neoplasms: between pancreatic cancer risk and discontinuation of extended surveillance. First author DOI 10.1136/gutjnl-2025-334807↗
  18. Recent Anti-KRAS G12D Therapies: A "Possible Impossibility" for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers17040704↗
  19. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  20. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  21. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  22. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  23. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  24. Simulation Model of Pancreatic Cancer Precursors Progression: "Timely" Surgery Does Not Equal "Opportune" (Anymore). First author DOI 10.1053/j.gastro.2023.09.037↗
  25. The Importance of Reading the Skin: Cutaneous Metastases of Pancreatic Cancer, a Systematic Review. Last author DOI 10.3390/jcm13010104↗
  26. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  27. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  28. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004845↗
  29. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy i… Co-author DOI 10.1186/s12885-021-07877-7↗
  30. Neoadjuvant therapy in resectable pancreatic cancer-is this the way forward?-a narrative review. First author DOI 10.21037/cco-21-51↗
  31. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Co-author DOI 10.3390/cancers13133119↗
  32. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32586↗
  33. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  34. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2020.04.006↗
  35. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  36. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08354-4↗
  37. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
  38. Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. Co-author DOI 10.3390/cancers11020267↗
  39. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗
  40. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 re… Co-author DOI 10.1007/s00330-018-5410-6↗
  41. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Co-author DOI 10.1007/s00423-017-1627-0↗
  42. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.hpb.2017.10.017↗
  43. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Co-author DOI 10.1016/j.pan.2018.04.002↗
  44. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications. Co-author DOI 10.1245/s10434-017-6281-9↗
  45. ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer. First author DOI 10.1245/s10434-018-6874-y↗
  46. Pancreatic Cancer in the Era of Neoadjuvant Therapy: A Narrative Overview. First author DOI 10.21614/chirurgia.113.3.307↗
  47. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM. Co-author DOI 10.1097/sla.0000000000001837↗
  48. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. First author DOI 10.1097/sla.0000000000000867↗
  49. Pancreaticoduodenectomy for pancreatic cancer: the Verona experience. First author DOI 10.1007/s00595-010-4419-5↗

Closest collaborators

The 25 strongest of 186 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giampaolo Perri · 13 shared papers, 2018–2026 · strength 3.68
  2. Roberto Salvia · 24 shared papers, 2011–2026 · strength 2.49
  3. Giuseppe Malleo · 20 shared papers, 2011–2024 · strength 1.91
  4. Umberto Cillo · 6 shared papers, 2023–2026 · strength 1.65
  5. Claudio Bassi · 19 shared papers, 2011–2024 · strength 1.65
  6. Aya Maekawa · 4 shared papers, 2026 · strength 1.53
  7. Salvatore Paiella · 10 shared papers, 2018–2022 · strength 0.92
  8. Laura Maggino · 10 shared papers, 2017–2022 · strength 0.88
  9. Aldo Scarpa · 9 shared papers, 2017–2024 · strength 0.88
  10. Samuele Grandi · 3 shared papers, 2025–2026 · strength 0.87
  11. Gabriele Capurso · 2 shared papers, 2025–2026 · strength 0.73
  12. Marc G. Besselink · 6 shared papers, 2018–2026 · strength 0.72
  13. Claudio Luchini · 6 shared papers, 2020–2024 · strength 0.71
  14. Matteo De Pastena · 7 shared papers, 2018–2026 · strength 0.68
  15. Ingmar Florin Rompen · 3 shared papers, 2025–2026 · strength 0.61
  16. Agata Grochowska · 2 shared papers, 2026 · strength 0.60
  17. Stefano Crippa · 2 shared papers, 2025 · strength 0.60
  18. Joseph R. Habib · 3 shared papers, 2024–2026 · strength 0.54
  19. Ammar A. Javed · 3 shared papers, 2024–2026 · strength 0.54
  20. Christopher Lee Wolfgang · 3 shared papers, 2020–2026 · strength 0.51
  21. Mirko D’Onofrio · 6 shared papers, 2018–2024 · strength 0.50
  22. Riccardo Guastella · 2 shared papers, 2025–2026 · strength 0.49
  23. Thilo Hackert · 3 shared papers, 2022–2026 · strength 0.46
  24. Alessandro Esposito · 5 shared papers, 2018–2024 · strength 0.45
  25. Jörg Kaiser · 3 shared papers, 2022–2025 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.